Novo Nordisk links with Kallyope to tackle obesity, diabetes

19 June 2018

Novo Nordisk (NOV: N) has announced a collaboration with Kallyope, a privately-held New York biotechnology platform developer, with the aim of developing novel therapies for diabetes and obesity.

The focus of their efforts will be the potential applications of peptides in the 'gut-brain axis', the system of biochemical signalling between the gastrointestinal tract and the central nervous system.

The deal will allow the Danish diabetes specialist to use Kallyope's unique development platform to target the gut-brain axis with novel biologics. Kallyope is set to contribute to the discovery process, though Nordisk will be solely responsible for any further drug development.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK